Patent application number | Description | Published |
20100108218 | EXTENSIBLE NON-LOAD BEARING CUT RESISTANT TIRE SIDE-WALL COMPONENT COTAINING ELASTOMERIC FILAMENT, TIRE CONTAINING SAID COMPONENT, AND PROCESSES FOR MAKING SAME - This invention relates to a cut resistant tire side-wall component and processes for making such components, and a tire containing such component, the side-wall component comprising a textile fabric wherein a single layer of said fabric provides multi-directional cut resistance in the plane of the fabric, | 05-06-2010 |
20100108225 | Non-Load Bearing Cut Resistant Tire Side-wall Component Comprising Knitted Textile Fabric, Tire Containing Said Component, and Processes for Making Same - This invention relates to cut-resistant tire side-wall components and tires having same, the tire side-wall components comprising at least a single layer of knitted textile fabric providing multi-directional cut resistance; the fabric comprising a first yarn having cut resistant polymeric fiber and a second yarn having inorganic fiber; the fabric further having a coating for good adhesion of the fabric to rubber such that the cut resistant tire side wall component has a free area of from 18 to 65 percent. | 05-06-2010 |
20100108231 | NON-LOAD BEARING CUT RESISTANT TIRE SIDE- WALL COMPONENT AND TIRE CONTAINING SAID COMPONENT, AND PROCESSES FOR MAKING SAME - This invention relates to a cut resistant tire side-wall component and processes for making such components, and a tire containing such component, the side-wall component comprising a textile fabric wherein a single layer of said fabric provides multi-directional cut resistance in the plane of the fabric, the fabric comprising at least one single yarn having a sheath/core construction, the sheath comprising cut-resistant polymeric staple fibers and the core comprising an inorganic fiber, the fabric further having a coating for improved adhesion of the fabric to rubber such that the cut resistant tire side-wall component has a free area of from 18 to 65 percent. | 05-06-2010 |
20110000264 | Stain masking cut resistant gloves and processes for making same - This invention also relates to stain-masking cut resistant gloves and methods for making the same, the gloves comprising at least one aramid fiber and at least one lubricating fiber selected from the group consisting of aliphatic polyamide fiber, polyolefin fiber, polyethylene fiber, acrylic fiber, and mixtures thereof; wherein up to and including 15 parts by weight of the total amount of fibers in the glove are provided with a dye or pigment such that they have a color different from the remaining fibers; the dye or pigment selected such that the colored fibers have a measured “L” value that is lower than the measured “L” value for the remaining fibers. | 01-06-2011 |
20140165251 | Cut Resistant Articles - A cut resistant article comprising a glove, sleeve, or apron comprising a knit fabric having yarns of fibers having essentially a round cross section and comprising linear polyethylene having a weight average molecular weight of at least 1 million, the yarns having a tensile modulus equal to 500 grams per denier (455 grams per dtex) or less and a yarn elongation at break of 4 percent or greater, the fabric further having a basis weight of 857 grams per square meter or less and having a mass index of 6000 or less. | 06-19-2014 |
Patent application number | Description | Published |
20110262437 | USE OF ERBB4 AS A PROGNOSTIC AND THERAPEUTIC MARKER FOR MELANOMA - It is disclosed herein that members of the protein tyrosine kinase (PTK) family are highly mutated in patients with melanoma. Described herein are novel somatic mutations in the ERBB4 gene that result in increased kinase activity, transformation ability and anchorage-independent growth. These ERBB4 mutations contribute to the tumorogenicity of melanoma. Thus, provided herein is a method of predicting the prognosis of a patient with melanoma by detecting the presence or absence of a mutation in the ERBB4 gene. In some examples, the ERBB4 mutation is selected from G949A, G1354A, G1624A, C1630T, G1687A, G2506A and G2614A (numbering based on SEQ ID NO: 1). Also provided are methods of selecting a patient as a candidate for treatment with an ERBB4 and/or PI3K/AKT pathway inhibitor, and a method of identifying a therapeutic agent for the treatment of a subject diagnosed with melanoma. Oligonucleotides that specifically hybridize with an ERBB4 nucleic acid molecule comprising a novel mutation, and arrays comprising such oligonucleotides, are also provided. | 10-27-2011 |
20130190374 | GRM3 MUTATIONS AND USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF MELANOMA - Described herein is a G-protein coupled receptor (GPCR)-directed mutational analysis of tumor DNA obtained from melanoma tissue samples. The GPCR gene glutamate receptor, metabotropic 3 (GRM3) was identified as the most highly mutated GPCR gene in this screen. Functional characterization of GRM3 mutants revealed that these mutants promote activation of MEK, anchorage-independent cell growth and metastasis. Thus, provided herein are methods of diagnosing a subject as having melanoma, or susceptible to developing melanoma, by detecting the presence of at least one mutation in GRM3. Also provided are methods of treating a subject with melanoma by detecting the presence of at least one mutation in GRM3 and administering an appropriate therapy. Further provided are methods of selecting a subject diagnosed with melanoma as a candidate for treatment with a GRM3 inhibitor, an MEK inhibitor, or both, by detecting the presence of at least one mutation in GRM3. | 07-25-2013 |
20140141431 | USE OF ERBB4 AS A PROGNOSTIC AND THERAPEUTIC MARKER FOR MELANOMA - Members of the protein tyrosine kinase (PTK) family are highly mutated in patients with melanoma. Described herein are novel somatic mutations in the ERBB4 gene that result in increased kinase activity, transformation ability and anchorage-independent growth. These ERBB4 mutations contribute to the tumorogenicity of melanoma. Provided is a method of predicting the prognosis of a patient with melanoma by detecting the presence or absence of a mutation in the ERBB4 gene. In some examples, the ERBB4 mutation is selected from G949A, G1354A, G1624A, C1630T, G1687A, G2506A and G2614A (numbering based on SEQ ID NO: 1). Also provided are methods of selecting a patient as a candidate for treatment with an ERBB4 and/or PI3K/AKT pathway inhibitor, and a method of identifying a therapeutic agent for the treatment of a subject diagnosed with melanoma. Oligonucleotides that specifically hybridize with an ERBB4 nucleic acid molecule comprising a novel mutation are also provided. | 05-22-2014 |